Global Pneumonia Vaccines Market By Vaccine Type (Pneumococcal conjugate vaccine (PCV) and Pneumococcal polysaccharide vaccine (PPSV/PPV)), By Product Type (Prevnar 13, Synflorix and Pneumovax23), By sector (Public sector and Private sector), By Distribution Channel (Distribution partner companies, Non-governmental Organizations (NGO) and Government Authorities)
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Pneumonia Vaccines Market
The Global Pneumonia Vaccines Market size is expected to reach $9.6 billion by 2025, rising at a market growth of 5.1% CAGR during the forecast period.
Pneumonia is a lung infection that occurs in one or both the lungs caused by bacteria, virus, or fungi; however, bacterial pneumonia is the most common form occurring in adults. Pneumonia results in inflammation in the air sacs (known as alveoli) of the lungs thereby filling the alveoli with fluid (pus cells), thus causing breathing problems. Pneumococcal disease is common in young children, but older adults are at the greatest risk of serious pneumococcal infections and even death. Pneumonia vaccines are primarily administered to children less than 2-years old and adults aged 65 years and older. This vaccine helps individuals provide immunization against 13 types of pneumococcal bacteria that cause infection in the lungs.
Global Pneumonia Vaccines Market Size
The key factors that drive the growth of the global pneumonia vaccine market include an increase in the prevalence of pneumonia across the globe, rise in government focus on immunization programs for pneumonia, and introduction of novel pneumococcal vaccines such as PCV10. However, longer timelines required for pneumonia vaccine production and high costs associated with the development of such vaccines restrain the market growth.
Based on Vaccine Type, the market is segmented into Pneumococcal conjugate vaccine (PCV) and Pneumococcal polysaccharide vaccine (PPSV/PPV). Based on Product Type, the market is segmented into Prevnar 13, Synflorix and Pneumovax23. According to sector, the market is segmented into Public sector and Private sector. Based on Distribution Channel, the market is further segmented into Distribution partner companies, Non-governmental Organizations (NGO) and Government Authorities. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.
Global Pneumonia Vaccines Market Share
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glaxosmithkline Plc. (GSK), LG Corporation, Panacea Biotec Limited, Pfizer, Inc., Pnuvax Incorporated, Poonawalla Investments & Industries Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., SK Holdings Co., Ltd., Walvax Biotechnology Co., Ltd. and MERCK & CO., Inc.
Scope of the Pneumonia Vaccines Market Analysis
By Vaccine Type
- Pneumococcal conjugate vaccine (PCV)
- Pneumococcal polysaccharide vaccine (PPSV/PPV)
By Product Type
- Prevnar 13
- Public sector
- Private sector
By Distribution Channel
- Distribution partner companies
- Non-governmental Organizations (NGO)
- Government Authorities
- North America
- Rest of North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Glaxosmithkline Plc. (GSK)
- LG Corporation
- Panacea Biotec Limited
- Pfizer, Inc.
- Pnuvax Incorporated
- Poonawalla Investments & Industries Pvt. Ltd.
- Shenzhen Kangtai Biological Products Co., Ltd.
- SK Holdings Co., Ltd.
- Walvax Biotechnology Co., Ltd.
- Merck & Co., Inc.
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free